US$ 20.17
astrocyte sxc glutamate transporter glutathione The rise of astrocytes: are they guardians or troublemakers of the brain disorder? Promotion of astrocyte-neuron glutamate-glutamine shuttle
Description
Phase 2a MASH data showed up to 82% liver fat reduction

These dietary restrictions can lead to insufficient levels of this crucial nutrient, increasing the risk of deficiency-related health issues

A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans. Frontiers in Pharmacology , vol

A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Nave or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive Induction Therapy
